Stock Markets June 19, 2026 04:13 AM

Synthomer Agrees to Sell Czech Acrylate Monomers Unit to Mutares

Transaction removes capital-intensive upstream business as Synthomer narrows focus on specialty chemicals

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn

Synthomer plc has reached an agreement to divest Synthomer a.s., its Acrylate Monomers operating company in the Czech Republic, to German turnaround investor Mutares SE & Co. KGaA. The Sokolov manufacturing site, which supplies acrylic acid and related monomers to the European merchant market and supports some internal downstream operations, employs about 300 people. Supply arrangements to Synthomer group companies will continue after the sale. The unit was identified as non-core in a strategic review in October 2022 and is the last upstream business in Synthomer's portfolio.

Synthomer Agrees to Sell Czech Acrylate Monomers Unit to Mutares
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Synthomer agreed to sell Synthomer a.s., its Czech Acrylate Monomers operating company, to Mutares SE & Co. KGaA.
  • The Sokolov facility employs around 300 people, supplies acrylic acid and related monomers to the European merchant market, and will continue supplying group companies post-sale.
  • The disposal removes a capital-intensive upstream business from Synthomer, advancing a shift toward higher-margin specialty chemicals.

Synthomer plc announced that it has entered into an agreement to sell Synthomer a.s., the company that operates its Acrylate Monomers business in the Czech Republic, to Mutares SE & Co. KGaA, a listed German private equity and turnaround investor.

The Acrylate Monomers operation at Sokolov produces acrylic acid and related monomers for the European merchant market and employs about 300 staff at the manufacturing site. In addition to serving external customers, the facility supplies acrylic monomers to other Synthomer group companies and manufactures acrylic dispersions used by the group. Those internal supply arrangements will remain in place following completion of the transaction.

Within Synthomer's corporate structure, Acrylate Monomers is housed in the Health & Protection and Performance Materials division. The unit participates in cyclical commodity markets and is described by the company as one of the more capital-intensive elements of its portfolio. It is also the only remaining upstream business in Synthomer's lineup. Management had flagged the unit as non-core during a strategic review that was announced in October 2022.

The planned disposal is intended to remove a cyclical, capital-heavy base chemicals activity from Synthomer's operations and accelerate the group's transition toward specialty chemicals. According to the company, the move aligns with a broader strategic aim to simplify the business and concentrate on higher-margin, higher-growth specialty markets where Synthomer holds leadership positions.

Synthomer's chief executive, Michael Willome, said the sale represents another step in simplifying operations and sharpening the company’s focus on specialty chemicals. He noted that Mutares, which invests in industrial turnarounds, is well positioned to support the Acrylate Monomers business in its further development.

The transaction preserves the existing supply relationships between the Sokolov site and other Synthomer group companies, ensuring continuity for downstream operations that rely on acrylic monomers and dispersions produced at the facility.


Background details

  • The Sokolov plant supplies acrylic acid and related monomers to the European merchant market.
  • The site employs approximately 300 people and also supplies internal group operations.
  • The Acrylate Monomers unit was identified as non-core in an October 2022 strategic review and is the only remaining upstream business within Synthomer.

Risks

  • The Acrylate Monomers business operates in cyclical markets, exposing the unit and related supply chains to demand volatility - this affects base chemicals and downstream specialty chemical users.
  • The operation is capital-intensive, which could present financial and execution risks for any new owner undertaking turnaround activity - this impacts industrial investors and suppliers.
  • As the last upstream asset for Synthomer, its sale alters internal supply arrangements; although existing supplies will continue, any future disruption could affect Synthomer's downstream operations and customers.

More from Stock Markets

Admiral Shares Slide After RBC Downgrade Cites Lagging UK Motor Pricing Jun 19, 2026 Vestas Shares Climb After J.P. Morgan Flags Possible Guidance Upgrade Jun 19, 2026 TSX Futures Stall as Canceled U.S.-Iran Talks Inject Uncertainty; Oil Edges Up, Gold Slips Jun 19, 2026 PPHE Hotel Shares Plunge After Fattal Withdraws Takeover Bid Jun 19, 2026 Evonik Rises After Deutsche Bank Predicts Significant Q2 Upside, Lifts Target Jun 19, 2026